News – Page 1110 – Endpoints News

Ben-Gurion University seeking partner to repurpose old lymphoma drug to treat ALS

8 years ago

Deciphera banks a $52M C round for cancer R&D; Ionis adds $50M milestone from Biogen

8 years ago

Leerink spotlights Novartis’ late-stage stars plus one utility player — suggesting where it could make deals

8 years ago

BRIEF: Deciphera bags a $52M round to back its cancer drug pipeline work

8 years ago

Scientist-turned-VC: Kevin Bitterman takes his biotech hatching experience to a new role at Atlas

8 years ago

New report heralds a revolution in cancer R&D trends - and the sticker shock that comes with it

8 years ago

Bicycle Therapeutics banks a $52M B round for the next leg of the long R&D journey ahead

8 years ago

Tesaro is reportedly on the auction block, but who can afford it?

8 years ago

Teva's CGRP migraine drug aces PhIII while rivals pile up at the FDA finish line

8 years ago

Nicox shares soar on Zerviate OK; Gemphire CEO resigns; Array, Ono team up on a $187M deal

8 years ago

China biotech startup InventisBio bags a $19M round for early-stage R&D

8 years ago

Scripps researchers add power to antibiotic vancomycin, giving it a third mechanism to fight superbugs

8 years ago

Alnylam preps for another PhIII RNAi study, ‘breakthrough’ status in hand

8 years ago

$420M fund comes to LYFE, with plans for a trans-Pacific investment strategy introducing US biotechs to China

8 years ago

Akari CEO abruptly resigns as a special committee moves a PhII patient success into the fail column

8 years ago

Another old, cheap generic is being prepped for an FDA application — made over into a ‘new’ drug for ADHD and ...

8 years ago

Novartis isn’t messing around with CAR-T, and it has a promising next-gen therapy to help prove it

8 years ago

Medicare drug rebates reward industry players — and often hurt patients

8 years ago

Gilead racing to FDA with a new HIV cocktail boasting megablockbuster potential

8 years ago

MannKind elevates Castanga to CEO; 23andMe recruits 5,000 women for study in 9 days

8 years ago

Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio

8 years ago

Prepping for ASCO? Investor Brad Loncar offers his own breakdown of what to watch for

8 years ago

Bristol-Myers Squibb adds to its roster of checkpoint combo studies, partnering with Array and Advaxis

8 years ago

J&J buys into Protagonist’s next-gen peptide story with $50M upfront and $940M in milestones

8 years ago

First page Previous page 1107 1108 110911101111 1112 1113 Next page Last page